| 摘要 |
Detecting a genetic predisposition in a human subject for non-responsiveness to statin drug treatment, comprising amplifying nucleic acids including a non-coding or untranslated region within the 3' end of the human lipoprotein lipase (LPL) gene from a tissue sample, and analyzing the products for homozygosity for a variant allele, is new.. Independent claims are also included for the following: (1) oligonucleotide primers for detecting a genetic predisposition for non-responsiveness to statin drug treatment in a human, where the primers include: (a) one of 55 forward primers comprising a 17, 18, 19, 20, 21, 22, 24, 25, 26 or 28 base pair sequence, or comprising a sequence overlapping any of the sequences with respect to its position on the Nickerson reference sequence comprising a 9734 base pair sequence, all fully defined in the specification; (b) one of 7 forward primers comprising a 20, 21, 22 or 25 base pair sequence, or comprising a sequence overlapping any of the sequences with respect to its position on the Oka reference sequence, comprising a 3240 base pair sequence, all fully defined in the specification; (c) one of 35 reverse primers comprising a 15, 17, 20, 21, 22, 24, 25 or 26 base pair sequence all fully defined in the specification, or comprising a sequence overlapping any of the sequences with respect to its position on the Nickerson reference sequence; or (d) one of 5 reverse primers comprising a 23, 24 or 25 base pair sequence all fully defined in the specification, or comprising a sequence overlapping any of the sequences with respect to its position on the Oka reference sequence; and (2) genetic testing kits comprising the primers of (1). |
